Abstract: The present disclosure relates to an organic electroluminescent compound, a plurality of host materials, and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure or by comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, it is possible to produce an organic electroluminescent device having improved luminous efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: Disclosed herein is a method of printing a nanostructure including: preparing a template substrate on which a pattern is formed; forming a replica pattern having an inverse phase of the pattern by coating a polymer thin film on an upper portion of the template substrate, adhering a thermal release tape to an upper portion of the polymer thin film, and separating the polymer thin film from the template substrate; forming a nanostructure by depositing a functional material on the replica pattern; and printing the nanostructure deposited on the replica pattern to a substrate by positioning the nanostructure on the substrate, applying heat and pressure to the nanostructure, and weakening an adhesive force between the thermal release tape and the replica pattern by the heat.

Abstract: Disclosed herein is a method of depositing a transition metal single-atom catalyst including preparing a carbon carrier, and depositing a transition metal single-atom catalyst on the carbon carrier, in which the carbon carrier is surface-treated by an oxidation process, and wherein the deposition is carried out by an arc plasma process.

Abstract: Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment.

Abstract: Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment.